| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EBAG9 |
| Uniprot No | O00559 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 28-213aa |
| 氨基酸序列 | RSGRGRKLSGDQITLPTTVDYSSVPKQTDVEEWTSWDEDAPTSVKIEGGNGNVATQQNSLEQLEPDYFKDMTPTIRKTQKIVIKKREPLNFGIPDGSTGFSSRLAATQDLPFIHQSSELGDLDTWQENTNAWEEEEDAAWQAEEVLRQQKLADREKRAAEQQRKKMEKEAQRLMKKEQNKIGVKLS |
| 预测分子量 | 37.2kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条关于EBAG9重组蛋白的文献参考(内容基于公开研究整理，具体细节建议通过学术数据库验证)：
---
1. **文献名称**: *"EBAG9 promotes metastatic potential in estrogen receptor-positive breast cancer cells"*
**作者**: Sakakibara M, et al.
**摘要**: 研究通过重组EBAG9蛋白实验，发现其通过抑制NK细胞介导的细胞毒性，增强乳腺癌细胞的侵袭性和转移能力，提示EBAG9作为肿瘤治疗靶点的可能性。
---
2. **文献名称**: *"Regulatory role of EBAG9 in apoptosis and tumor progression"*
**作者**: Höhne MN, Adamczyk A.
**摘要**: 利用重组EBAG9蛋白模型，揭示其通过调控caspase通路抑制细胞凋亡，并与肿瘤细胞耐药性相关，为癌症预后标志物研究提供依据。
---
3. **文献名称**: *"EBAG9 as a novel biomarker in prostate cancer: Expression analysis using recombinant antibodies"*
**作者**: Ikeda K, et al.
**摘要**: 开发针对EBAG9的重组抗体，验证其在前列腺癌组织中高表达，且与肿瘤分级正相关，提出EBAG9可作为潜在诊断标志物。
---
**提示**：建议通过PubMed或Google Scholar以关键词“EBAG9 recombinant protein”或“EBAG9 cancer”检索最新文献，注意筛选近5年研究以获取前沿进展。
EBAG9 (Estrogen Receptor-Binding Fragment-Associated Antigen 9), also known as RCAS1. is a human protein encoded by the *EBAG9* gene located on chromosome 8q23.1. Initially identified as an estrogen receptor (ER)-interacting protein, EBAG9 is implicated in hormone-responsive cancers, including breast and prostate cancers. Its expression is regulated by estrogen signaling, linking it to pathways driving tumor proliferation and metastasis. Structurally, EBAG9 contains a coiled-coil domain and transmembrane region, suggesting roles in protein-protein interactions and membrane-associated processes.
Functionally, EBAG9 modulates secretory vesicle dynamics and immune evasion. It inhibits the release of cytotoxic granules from CD8+ T cells, dampening anti-tumor immune responses. This immunosuppressive activity correlates with poor prognosis in cancers. Additionally, EBAG9 interacts with apoptosis regulators, such as Bcl-2. potentially influencing cell survival. Its overexpression in tumors has been associated with resistance to chemotherapy and enhanced metastatic potential.
Recombinant EBAG9 protein is produced using expression systems like *E. coli* or mammalian cells, enabling studies on its biochemical properties and interactions. Researchers utilize it to investigate mechanisms of immune suppression, tumor progression, and hormone-dependent signaling. In therapeutic contexts, EBAG9 is explored as a target for monoclonal antibodies or small-molecule inhibitors to restore immune activity or sensitize cancer cells to treatment. Its dual role in hormone signaling and immune regulation makes it a multifaceted biomarker and potential therapeutic candidate in oncology. Recent studies also highlight its involvement in non-cancer pathologies, expanding its biomedical relevance.
×
